The authors reported that the knockdown of ATM and ATR increased cell killing of glioblastoma and melanoma cells with a more significant effect in the ATR knockdown cells, suggesting that the combination of temozolomide with an ATR inhibitor might be a promising approach to fight temozolomide resistance. The gene discussed is ATR; the disease is glioblastoma.